Jean A Boutin

List of Publications by Year
in descending order

262	10,064	34105 52	51608 86
papers	citations	h-index	g-index

268	268	268	9717
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo. Molecular Biology Reports, 2022, 49, 149-161.	2.3	3
2	A Putative New Melatonin Binding Site in Sheep Brain, MTx: Preliminary Observations and Characteristics. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 76-89.	2.5	2
3	Caloxin-derived peptides for the inhibition of plasma membrane calcium ATPases. Peptides, 2022, 154, 170813.	2.4	2
4	Journal of pineal research guideline for authors: Defining and characterizing melatonin targets. Journal of Pineal Research, 2021, 70, e12712.	7.4	10
5	Melatonin controversies, an update. Journal of Pineal Research, 2021, 70, e12702.	7.4	35
6	MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice. Molecules, 2021, 26, 1291.	3.8	6
7	Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of Stryphnodendron pulcherrimum (Willd.) Hochr. Metabolites, 2021, 11, 281.	2.9	15
8	Apigenin and Luteolin Regulate Autophagy by Targeting NRH-Quinone Oxidoreductase 2 in Liver Cells. Antioxidants, 2021, 10, 776.	5.1	13
9	Constituents of Chamaecrista diphylla (L.) Greene Leaves with Potent Antioxidant Capacity: A Feature-Based Molecular Network Dereplication Approach. Pharmaceutics, 2021, 13, 681.	4.5	9
10	Association of NQO2 With UDP-Glucuronosyltransferases Reduces Menadione Toxicity in Neuroblastoma Cells. Frontiers in Pharmacology, 2021, 12, 660641.	3.5	2
11	Biochemistry, structure, and cellular internalization of a four nanobodyâ€bearing Fc dimer. Protein Science, 2021, 30, 1946-1957.	7.6	2
12	Chemical composition and antibacterial action of Stryphnodendron pulcherrimum bark extract, â€œbarbatimÃ£oâ€•species: Evaluation of its use as a topical agent. Arabian Journal of Chemistry, 2021, 14, 103183.	4.9	8
13	Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study. Molecules, 2021, 26, 4312.	3.8	1
14	VHH characterization.Recombinant VHHs: Production, characterization and affinity. Analytical Biochemistry, 2020, 589, 113491.	2.4	9
15	Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT₁ and MT₂ receptors. Pharmacology Research and Perspectives, 2020, 8, e00539.	2.4	22
16	The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion. Pharmacology Research and Perspectives, 2020, 8, e00556.	2.4	17
17	Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme. Molecular Pharmacology, 2020, 98, 620-633.	2.3	22
18	Secure and Sustainable Sourcing of Plant Tissues for the Exhaustive Exploration of Their Chemodiversity. Molecules, 2020, 25, 5992.	3.8	4

#	Article	IF	Citations
19	Identification of catalytic and nonâ€catalytic activity inhibitors against PRC2â€EZH2 complex through multiple highâ€throughput screening campaigns. Chemical Biology and Drug Design, 2020, 96, 1024-1051.	3.2	7
20	Melatonin receptor ligands: A pharmacoâ€chemical perspective. Journal of Pineal Research, 2020, 69, e12672.	7.4	39
21	Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes. Frontiers in Pharmacology, 2020, 11, 397.	3.5	126
22	The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells. Scientific Reports, 2019, 9, 11829.	3.3	48
23	VHH characterization. Comparison of recombinant with chemically synthesized antiâ€HER2 VHH. Protein Science, 2019, 28, 1865-1879.	7.6	16
24	Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. International Journal of Molecular Sciences, 2019, 20, 3181.	4.1	10
25	Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates. Molecules, 2019, 24, 3697.	3.8	8
26	General lack of structural characterization of chemically synthesized long peptides. Protein Science, 2019, 28, 857-867.	7.6	6
27	Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel. Toxicon: X, 2019, 2, 100010.	2.9	3
28	S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization. Molecular Pharmacology, 2019, 95, 269-285.	2.3	21
29	Is There Sufficient Evidence that the Melatonin Binding SiteMT₃Is Quinone Reductase 2?. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 59-65.	2.5	55
30	Melanin-concentrating hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
31	A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot. Journal of Biological Chemistry, 2018, 293, 9064-9077.	3.4	6
32	GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4501-4506.	7.1	55
33	Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2. Free Radical Biology and Medicine, 2018, 120, 56-61.	2.9	39
34	Assessments of cellular melatonin receptor signaling pathways: Î²-arrestin recruitment, receptor internalization, and impedance variations. European Journal of Pharmacology, 2018, 818, 534-544.	3.5	16
35	On the Organization of a Drug Discovery Platform. , 2018, , .		2
36	Hamster Melatonin Receptors: Cloning and Binding Characterization of MT1 and Attempt to Clone MT2. International Journal of Molecular Sciences, 2018, 19, 1957.	4.1	8

#	Article	IF	Citations
37	Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative. Journal of Medicinal Chemistry, 2018, 61, 10185-10197.	6.4	5
38	Gene expression profiling during hibernation in the European hamster. Scientific Reports, 2018, 8, 13167.	3.3	30
39	Natural Inhibitors of the RhoAâ€“p115 Complex from the Bark of Meiogyne baillonii. Journal of Natural Products, 2018, 81, 1610-1618.	3.0	8
40	A Chemical Library to Screen Protein and Proteinâ€“Ligand Crystallization Using a Versatile Microfluidic Platform. Crystal Growth and Design, 2018, 18, 5130-5137.	3.0	18
41	Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). PLoS ONE, 2018, 13, e0191904.	2.5	35
42	Microfluidic platform for optimization of crystallization conditions. Journal of Crystal Growth, 2017, 472, 18-28.	1.5	31
43	W2476 ameliorates Î²-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway. Acta Pharmacologica Sinica, 2017, 38, 1024-1037.	6.1	11
44	Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 174-183.	0.8	56
45	New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry, 2017, 127, 621-631.	5.5	9
46	Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides. Analytical Biochemistry, 2017, 519, 57-70.	2.4	4
47	Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBÎ±/NCoR. Journal of Computer-Aided Molecular Design, 2017, 31, 755-775.	2.9	31
48	Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 574-578.	0.8	15
49	Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives. Molecules, 2017, 22, 210.	3.8	7
50	New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. International Journal of Molecular Sciences, 2017, 18, 1347.	4.1	13
51	Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Proteinâ€“Ligand Residence Times. Journal of Medicinal Chemistry, 2016, 59, 7167-7176.	6.4	81
52	High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H44-H53.	3.2	70
53	Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6). Protein Science, 2016, 25, 2225-2242.	7.6	9
54	Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chemico-Biological Interactions, 2016, 258, 115-125.	4.0	32

#	Article	IF	Citations
55	Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 681-692.	2.5	24
56	Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. European Journal of Medicinal Chemistry, 2016, 109, 360-370.	5.5	8
57	Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles. Biochemistry, 2016, 55, 38-48.	2.5	85
58	Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opinion on Therapeutic Targets, 2016, 20, 303-317.	3.4	71
59	Molecular mechanisms of transcriptional control by Revâ€erbÎ±: An energetic foundation for reconciling structure and binding with biological function. Protein Science, 2015, 24, 1129-1146.	7.6	11
60	19F nuclear magnetic resonance screening of glucokinase activators. Analytical Biochemistry, 2015, 477, 62-68.	2.4	8
61	Highly Potent and Selective MT₂ Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. Journal of Medicinal Chemistry, 2015, 58, 7512-7525.	6.4	47
62	In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones. Free Radical Biology and Medicine, 2015, 89, 126-134.	2.9	38
63	Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). European Journal of Medicinal Chemistry, 2015, 90, 822-833.	5.5	9
64	Recombinant Human Melatonin Receptor MT1 Isolated in Mixed Detergents Shows Pharmacology Similar to That in Mammalian Cell Membranes. PLoS ONE, 2014, 9, e100616.	2.5	21
65	Melatonin <scp>MT₁</scp> and <scp>MT₂</scp> receptors display different molecular pharmacologies only in the <scp>G</scp>â€protein coupled state. British Journal of Pharmacology, 2014, 171, 186-201.	5.4	51
66	Molecular basis of agonist docking in a human <scp>GPR</scp>103 homology model by siteâ€directed mutagenesis and structureâ€“activity relationship studies. British Journal of Pharmacology, 2014, 171, 4425-4439.	5.4	13
67	Melatonin from Cerebrospinal Fluid but Not from Blood Reaches Sheep Cerebral Tissues Under Physiological Conditions. Journal of Neuroendocrinology, 2014, 26, 151-163.	2.6	57
68	Synthesis, chiral resolution, absolute configuration assignment and pharmacological evaluation of a series of melatoninergic ligands. MedChemComm, 2014, 5, 1303-1308.	3.4	4
69	New melatonin (MT1/MT2) ligands: Design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 986-996.	3.0	18
70	Synthesis and Pharmacological Evaluation of a series of the Agomelatine Analogues as Melatonin MT₁/MT₂ Agonist and 5â€HT_{2C} Antagonist. ChemMedChem, 2013, 8, 1830-1845.	3.2	16
71	New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors. International Journal of Molecular Sciences, 2013, 14, 8948-8962.	4.1	29
72	S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. Molecular Cancer Therapeutics, 2013, 12, 1749-1762.	4.1	78

#	Article	IF	Citations
73	High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with Anti-Diabetic Efficacy in db/db Mice. PLoS ONE, 2013, 8, e63861.	2.5	12
74	Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. Frontiers in Endocrinology, 2012, 3, 160.	3.5	12
75	S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/Î±₂-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 750-764.	2.5	14
76	Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity. ChemMedChem, 2012, 7, 2179-2193.	3.2	13
77	Rational Design of a Low Molecular Weight, Stable, Potent, and Long-Lasting GPR103 Aza-Î²3-pseudopeptide Agonist. Journal of Medicinal Chemistry, 2012, 55, 7516-7524.	6.4	27
78	Mutagenic analysis in a pure molecular system shows that thioredoxinâ€interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin. Protein Science, 2012, 21, 1323-1333.	7.6	5
79	Description of the constitutive activity of cloned human melatonin receptors hMT₁ and hMT₂ and discovery of inverse agonists. Journal of Pineal Research, 2012, 53, 29-37.	7.4	18
80	Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry. International Journal of Mass Spectrometry, 2012, 312, 87-96.	1.5	12
81	Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European Journal of Medicinal Chemistry, 2012, 49, 310-323.	5.5	29
82	Molecular pharmacology of the mouse melatonin receptors MT1 and MT2. European Journal of Pharmacology, 2012, 677, 15-21.	3.5	24
83	Structureâ€“Activity Relationships of a Series of Analogues of the RFamide-Related Peptide 26RFa. Journal of Medicinal Chemistry, 2011, 54, 4806-4814.	6.4	34
84	Insights into the redox cycle of human quinone reductase 2. Free Radical Research, 2011, 45, 1184-1195.	3.3	53
85	Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. Life Sciences, 2011, 89, 259-268.	4.3	10
86	The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions. Frontiers in Neuroendocrinology, 2011, 32, 387-397.	5.2	53
87	Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 2517-2528.	3.0	63
88	The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 929-935.	2.5	53
89	Xâ€ray structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Science, 2011, 20, 1182-1195.	7.6	38
90	Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2316-2319.	2.2	15

#	Article	IF	Citations
91	Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. European Journal of Medicinal Chemistry, 2011, 46, 1622-1629.	5.5	14
92	Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. European Journal of Medicinal Chemistry, 2011, 46, 1835-1840.	5.5	24
93	Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA). Journal of Neuroscience, 2011, 31, 16928-16940.	3.6	80
94	A Quantitative Assay for Lysosomal Acidification Rates in Human Osteoclasts. Assay and Drug Development Technologies, 2011, 9, 157-164.	1.2	3
95	Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells. PLoS ONE, 2011, 6, e17237.	2.5	38
96	Receptor- and Ligand-Based Study on Novel 2,2â€²-Bithienyl Derivatives as Non-Peptidic AANAT Inhibitors. Journal of Chemical Information and Modeling, 2010, 50, 446-460.	5.4	3
97	Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2010, 18, 3426-3436.	3.0	21
98	Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. BMC Musculoskeletal Disorders, 2010, 11, 250.	1.9	18
99	Old and new inhibitors of quinone reductase 2. Chemico-Biological Interactions, 2010, 186, 103-109.	4.0	47
100	Molecular and cellular pharmacological properties of 5â€•methoxycarbonylaminoâ€•N â€•acetyltryptamine (MCAâ€•NAT): a nonspecific MT3 ligand. Journal of Pineal Research, 2010, 48, 222-229.	7.4	34
101	Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. Journal of Pineal Research, 2010, 48, 263-269.	7.4	54
102	Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors. Journal of Neuroscience, 2010, 30, 12690-12700.	3.6	49
103	Meganuclease-Driven Targeted Integration in CHO-K1 Cells for the Fast Generation of HTS-Compatible Cell-Based Assays. Journal of Biomolecular Screening, 2010, 15, 956-967.	2.6	30
104	Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 653-672.	5.2	2
105	Autotaxin. Cellular and Molecular Life Sciences, 2009, 66, 3009-3021.	5.4	44
106	The end of a myth: cloning and characterization of the ovine melatonin MT₂ receptor. British Journal of Pharmacology, 2009, 158, 1248-1262.	5.4	54
107	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2683-2687.	2.2	17
108	Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. Bioorganic and Medicinal Chemistry, 2009, 17, 2963-2974.	3.0	19

#	Article	IF	Citations
109	A Dimeric Sesquiterpenoid from a Malaysian Meiogyne as a New Inhibitor of Bcl-xL/BakBH3 Domain Peptide Interaction. Journal of Natural Products, 2009, 72, 480-483.	3.0	42
110	Image-free assessment of protein translocation in live cells. Current Opinion in Pharmacology, 2009, 9, 650-656.	3.5	4
111	Progress and new fields in molecular pharmacology. Current Opinion in Pharmacology, 2009, 9, 577-579.	3.5	0
112	S38151 [p-guanidinobenzoyl-[Des-Gly10]-MCH(7-17)] is a potent and selective antagonist at the MCH1 receptor and has anti-feeding properties in vivo. Peptides, 2009, 30, 1997-2007.	2.4	10
113	Binding Kinetics of Glucose and Allosteric Activators to Human Glucokinase Reveal Multiple Conformational States. Biochemistry, 2009, 48, 5466-5482.	2.5	47
114	Cytotoxic Pentacyclic Triterpenoids from Combretum sundaicum and Lantana camara as Inhibitors of Bcl-xL/BakBH3 Domain Peptide Interaction. Journal of Natural Products, 2009, 72, 1314-1320.	3.0	33
115	Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-Dimethyl-3,4-dihydro-1H-quinolin-2-one. European Journal of Medicinal Chemistry, 2008, 43, 1730-1736.	5.5	11
116	Synthesis of 3-phenylnaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2008, 16, 8339-8348.	3.0	22
117	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part I: Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1617-1622.	2.2	36
118	High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1. Acta Pharmacologica Sinica, 2008, 29, 752-758.	6.1	15
119	High-throughput screening assay for new ligands at human melatonin receptors. Acta Pharmacologica Sinica, 2008, 29, 1515-1521.	6.1	13
120	MT3/QR2 melatonin binding site does not use melatonin as a substrate or a coâ€substrate. Journal of Pineal Research, 2008, 45, 524-531.	7.4	37
121	Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. British Journal of Pharmacology, 2008, 154, 1182-1195.	5.4	244
122	Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochemical Pharmacology, 2008, 75, 2007-2019.	4.4	41
123	Molecular pharmacology of adipocyte-secreted autotaxin. Chemico-Biological Interactions, 2008, 172, 115-124.	4.0	17
124	Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. Archives of Biochemistry and Biophysics, 2008, 477, 12-19.	3.0	18
125	A Generic Approach for the Purification of Signaling Complexes That Specifically Interact with the Carboxyl-terminal Domain of G Protein-coupled Receptors. Molecular and Cellular Proteomics, 2008, 7, 1556-1569.	3.8	31
126	Murine and Human Autotaxin Î±, Î², and Î³ Isoforms. Journal of Biological Chemistry, 2008, 283, 7776-7789.	3.4	109

#	Article	IF	Citations
127	S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological Tool. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 809-819.	2.5	89
128	Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochemical Journal, 2008, 413, 81-91.	3.7	81
129	Synthesis of a Novel Series of 8-HETE Analogs and their Biological Evaluation Towards the PPAR Nuclear Receptors. Letters in Drug Design and Discovery, 2008, 5, 503-511.	0.7	3
130	Comment on "Obestatin, a Peptide Encoded by the Ghrelin Gene, Opposes Ghrelin's Effects on Food Intake". Science, 2007, 315, 766-766.	12.6	178
131	Cellular knock-down of quinone reductase 2: A laborious road to successful inhibition by RNA interference. Biochimie, 2007, 89, 1264-1275.	2.6	16
132	Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. British Journal of Pharmacology, 2007, 150, 37-46.	5.4	89
133	Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. Journal of Pineal Research, 2007, 43, 10-15.	7.4	21
134	Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. FEBS Letters, 2007, 581, 3572-3578.	2.8	57
135	S18986: A positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. European Journal of Pharmacology, 2007, 561, 23-31.	3.5	20
136	Resistance to high-fat-diet-induced obesity and sexual dimorphism in the metabolic responses of transgenic mice with moderate uncoupling protein 3 overexpression in glycolytic skeletal muscles. Diabetologia, 2007, 50, 2190-2199.	6.3	48
137	Therapeutic Potential of Melatonin Ligands. Chronobiology International, 2006, 23, 413-418.	2.0	45
138	Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose. Biochemical Journal, 2006, 393, 431-439.	3.7	48
139	The use ofÂIRES-based bicistronic vectors allows theÂstable expression ofÂrecombinant G-protein coupled receptors such asÂNPY5 andÂhistamine 4. Biochimie, 2006, 88, 737-746.	2.6	11
140	A microplate assay for the screening of ADAMTS-4 inhibitors. Matrix Biology, 2006, 25, 261-267.	3.6	7
141	New ligands at theÂmelatonin binding site MT3. European Journal of Medicinal Chemistry, 2006, 41, 306-320.	5.5	83
142	Assessment of a high-throughput screening methodology for the measurement of purified UCP1 uncoupling activity. Analytical Biochemistry, 2006, 351, 201-206.	2.4	9
143	A Simple Theoretical Model for Fluorescence Polarization Binding Assay Development. Journal of Biomolecular Screening, 2006, 11, 949-958.	2.6	22
144	Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochemical Journal, 2005, 388, 205-215.	3.7	73

#	Article	IF	Citations
145	Quinone reductase 2 substrate specificity and inhibition pharmacology. Chemico-Biological Interactions, 2005, 151, 213-228.	4.0	48
146	Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay. Cellular Signalling, 2005, 17, 489-496.	3.6	5
147	NRH:quinone reductase 2: An enzyme of surprises and mysteries. Biochemical Pharmacology, 2005, 71, 1-12.	4.4	135
148	Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochemical Pharmacology, 2005, 71, 74-88.	4.4	112
149	Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia, 2005, 48, 569-577.	6.3	104
150	Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARÎ³. Biochemical and Biophysical Research Communications, 2005, 337, 521-525.	2.1	39
151	Molecular tools to study melatonin pathways and actions. Trends in Pharmacological Sciences, 2005, 26, 412-419.	8.7	205
152	The Emergence of Selective 5-HT2B Antagonists Structures, Activities and Potential Therapeutic Applications [General Reviews]. Mini-Reviews in Medicinal Chemistry, 2004, 4, 325-330.	2.4	27
153	Design and Synthesis of Indole and Tetrahydroisoquinoline Hydantoin Derivatives as Human Chymase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 137-143.	5.2	8
154	A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. International Journal of Obesity, 2004, 28, 628-639.	3.4	22
155	Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochemical Pharmacology, 2004, 67, 667-677.	4.4	37
156	New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors. FEBS Journal, 2004, 271, 418-428.	0.2	15
157	Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors. European Journal of Medicinal Chemistry, 2004, 39, 515-526.	5.5	28
158	Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding siteMT3. FEBS Letters, 2004, 578, 116-120.	2.8	72
159	Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species. Protein Expression and Purification, 2004, 38, 84-98.	1.3	15
160	Comparative analysis of melanin-concentrating hormone structure and activity in fishes and mammals. Peptides, 2004, 25, 1623-1632.	2.4	19
161	New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 553-561.	3.0	224
162	Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 789-800.	3.0	10

#	Article	IF	Citations
163	Jean - Luc Fauchereâ€,(1941-2003). Chemical Biology and Drug Design, 2003, 62, 185-185.	1.1	0
164	Therapeutic Perspectives for Melatonin Agonists and Antagonists. Journal of Neuroendocrinology, 2003, 15, 442-448.	2.6	54
165	Endothelin-1 inhibits TNFÎ± -induced iNOS expression in 3T3-F442A adipocytes. British Journal of Pharmacology, 2003, 139, 935-944.	5.4	14
166	Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 753-759.	3.0	36
167	Design and Synthesis of Naphthalenic Dimers as Selective MT1Melatoninergic Ligands. Journal of Medicinal Chemistry, 2003, 46, 1127-1129.	6.4	61
168	In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles. Biochemical and Biophysical Research Communications, 2003, 311, 583-591.	2.1	9
169	Peroxisome Proliferator-activated Receptor Î³ (PPARÎ³) as a Molecular Target for the Soy Phytoestrogen Genistein. Journal of Biological Chemistry, 2003, 278, 962-967.	3.4	289
170	Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation. Journal of Biological Chemistry, 2003, 278, 18162-18169.	3.4	207
171	Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3. Journal of Biological Chemistry, 2003, 278, 15749-15757.	3.4	67
172	Design, Synthesis and In Vitro Evaluation of Novel Benzo[b]thiophene Derivatives as Serotonin N-acetyltransferase (AANAT) Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 119-125.	5.2	10
173	Synthesis of 5-Substituted-2,3-dihydro-1,4-benzoxathiins: Biological Evaluation as Melatonin Receptors Ligands. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 187-193.	5.2	8
174	Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. Biochemical Journal, 2003, 369, 667-673.	3.7	21
175	Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 409-414.	5.2	13
176	Uncoupling Protein-3 (UCP3) mRNA Expression in Reconstituted Human Muscle after Myoblast Transplantation in RAG2â^'/â^'/Î³c/C5â^' Immunodeficient Mice. Journal of Biological Chemistry, 2002, 277, 47407-47411.	3.4	14
177	Appetite-Boosting Property of Pro-Melanin-Concentrating Hormone131â€“165 (Neuropeptide-Glutamic) Tj ETQq1 1 0.784314 rgBT /O Therapeutics, 2002, 302, 766-773.	2.5	22
178	Synthesis of Nitroindole Derivatives with High Affinity and Selectivity for Melatoninergic Binding SitesMT3. Journal of Medicinal Chemistry, 2002, 45, 1853-1859.	6.4	39
179	Synthesis and Structureâ^'Affinityâ^'Activity Relationships of Novel Benzofuran Derivatives as MT2 Melatonin Receptor Selective Ligands. Journal of Medicinal Chemistry, 2002, 45, 2788-2800.	6.4	88
180	Melanin-concentrating hormone and its receptors: state of the art. Canadian Journal of Physiology and Pharmacology, 2002, 80, 388-395.	1.4	50

#	Article	IF	Citations
181	SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor. Biochemical and Biophysical Research Communications, 2002, 295, 841-848.	2.1	11
182	Expression and regulation of the nuclear receptor RORÎ± in human vascular cells. FEBS Letters, 2002, 511, 36-40.	2.8	50
183	Natural ligands of PPARÎ³:. Cellular Signalling, 2002, 14, 573-583.	3.6	123
184	Ligand modulation of [35S]GTPÎ³S binding at human Î±2A, Î±2B and Î±2C adrenoceptors. Cellular Signalling, 2002, 14, 829-837.	3.6	25
185	Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87). Cellular and Molecular Life Sciences, 2002, 59, 1395-1405.	5.4	16
186	Structure and Expression of the Human Histamine H4-Receptor Gene. Biochemical and Biophysical Research Communications, 2001, 284, 301-309.	2.1	139
187	Regulation of murine airway responsiveness by endothelial nitric oxide synthase. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L258-L267.	2.9	35
188	Parallel synthesis and pharmacological screening of nonpeptide ligands of the neuropeptide Y receptor subtype Y5. Chemical Biology and Drug Design, 2001, 57, 419-427.	1.1	2
189	From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors. Chemical Biology and Drug Design, 2001, 57, 85-96.	1.1	3
190	Development of new assays and improved procedures for the purification of recombinant human chymase. FEBS Journal, 2001, 268, 5885-5893.	0.2	7
191	[125 I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. British Journal of Pharmacology, 2001, 133, 371-378.	5.4	41
192	Comparative pharmacological studies of melatonin receptors: mt1, mt2 and mt3/qr2. tissue distribution of mt3/qr2 11Abbreviations: MCA-NAT, methoxy-carbonylamino-N-acetyltrypta- mine, 2-[125I]-I-MCA-NAT, 2-[125I]-iodomethoxy-carbonylamino-N-acetyltryptamine; 2-IbMT, 2-iodo-N-butanoyl-5-methoxytryptamine; 4-P-PDOT, 4-phenyl-2-propionamido-tetraline; DH97, N-pentanoyl-2-benzyltryptamine; S20760, 5-methoxy-N-cyclopropanoyl-tryptamine; S24635,		

#	Article	IF	Citations
199	Agonist and antagonist actions of yohimbine as compared to fluparoxan at ?2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse, 2000, 35, 79-95.	1.2	163
200	Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt 1 and MT 2 receptors. Bioorganic and Medicinal Chemistry, 2000, 8, 163-171.	3.0	15
201	Synthesis of Phenalene and Acenaphthene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors. Journal of Medicinal Chemistry, 2000, 43, 4051-4062.	6.4	35
202	Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT 2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 549-554.	3.0	7
203	Screening of Ligand Binding on Melatonin Receptor Using Non-Peptide Combinatorial Libraries. Journal of Receptor and Signal Transduction Research, 2000, 20, 105-118.	2.5	5
204	Substrate Specificity and Inhibition Studies of Human SerotoninN-Acetyltransferase. Journal of Biological Chemistry, 2000, 275, 8794-8805.	3.4	58
205	High-Capacity Screening of Arylalkylamine N-Acetyltransferase Inhibitors using a High-Performance Liquid Chromatography System. Journal of Biomolecular Screening, 2000, 5, 361-368.	2.6	9
206	Identification of the Melatonin-binding SiteMT 3 as the Quinone Reductase 2. Journal of Biological Chemistry, 2000, 275, 31311-31317.	3.4	493
207	Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. Canadian Journal of Physiology and Pharmacology, 2000, 78, 173-185.	1.4	54
208	Food intake regulation in rodents: Y₅ or Y₁ NPY receptors or both?. Canadian Journal of Physiology and Pharmacology, 2000, 78, 173-185.	1.4	42
209	Physico-chemical and biological analysis of true combinatorial libraries. Biomedical Applications, 1999, 725, 17-37.	1.7	11
210	NPY receptor subtype in the rabbit isolated ileum. British Journal of Pharmacology, 1999, 127, 795-801.	5.4	31
211	Investigation of S-Farnesyl Transferase Substrate Specificity with Combinatorial Tetrapeptide Libraries. Cellular Signalling, 1999, 11, 59-69.	3.6	21
212	Cloning and Characterization of the 5â€² Flanking Region of the Human Uncoupling Protein 3 (UCP3) Gene. Biochemical and Biophysical Research Communications, 1999, 258, 278-283.	2.1	101
213	Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human Î±1A-adrenoceptors. Biochemical Journal, 1999, 343, 231.	3.7	27
214	Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 334-40.	2.5	54
215	A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. European Journal of Pharmacology, 1998, 351, 225-233.	3.5	13
216	Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads. Chemometrics and Intelligent Laboratory Systems, 1998, 43, 43-68.	3.5	30

#	Article	IF	Citations
217	NPY receptor subtypes involved in the contraction of the proximal colon of the rat. Regulatory Peptides, 1998, 75-76, 221-229.	1.9	31
218	Chromatographic Assay and Peptide Substrate Characterization of Partially Purified Farnesyl- and Geranylgeranyltransferases from Rat Brain Cytosol. Archives of Biochemistry and Biophysics, 1998, 354, 83-94.	3.0	12
219	Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Canadian Journal of Physiology and Pharmacology, 1997, 75, 683-689.	1.4	9
220	Myristoylation. Cellular Signalling, 1997, 9, 15-35.	3.6	362
221	Limitations of the coupling of amino acid mixtures for the preparation of equimolar peptide libraries. Molecular Diversity, 1997, 3, 43-60.	3.9	18
222	Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Molecular Diversity, 1997, 2, 135-146.	3.9	30
223	Evaluation of high performance liquid chromatography/electrospray mass spectrometry with selected ion monitoring for the analysis of large synthetic combinatorial peptide libraries. Rapid Communications in Mass Spectrometry, 1997, 11, 1971-1976.	1.5	19
224	Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Canadian Journal of Physiology and Pharmacology, 1997, 75, 683-9.	1.4	4
225	Combinatorial peptide synthesis: statistical evaluation of peptide distribution. Trends in Pharmacological Sciences, 1996, 17, 8-12.	8.7	23
226	Combinatorial Peptide Libraries: Robotic Synthesis and Analysis by Nuclear Magnetic Resonance, Mass Spectrometry, Tandem Mass Spectrometry, and High-Performance Capillary Electrophoresis Techniques. Analytical Biochemistry, 1996, 234, 126-141.	2.4	65
227	Tyrosine protein kinase assays. Biomedical Applications, 1996, 684, 179-199.	1.7	8
228	Heterogeneity of Hepatic Microsomal UDP-Glucuronosyltransferase(s) Activities: A New Kinetic Approach for the Study of Induction and Specificity. Journal of Pharmaceutical Sciences, 1994, 83, 591-596.	3.3	3
229	Tyrosine protein kinase inhibition and cancer. International Journal of Biochemistry & Cell Biology, 1994, 26, 1203-1226.	0.5	57
230	Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HLâ€60. International Journal of Peptide and Protein Research, 1994, 43, 496-504.	0.1	8
231	Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60. FEBS Journal, 1993, 214, 503-514.	0.2	11
232	Myristoyl-CoA: protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210. FEBS Journal, 1993, 214, 853-867.	0.2	46
233	Studies of the potency of protein kinase inhibitors on ATPase activities. Chemico-Biological Interactions, 1993, 86, 17-27.	4.0	14
234	Integrated system for the screening of the specificity of protein kinase inhibitors. Biochemical Pharmacology, 1993, 46, 439-448.	4.4	21

#	Article	IF	Citations
235	Heterogeneity of hepatic UDP-Glucuronosyltransferase activities: Investigations of isoenzymes involved in p-nitrophenol glucuronidation. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1993, 106, 241-248.	0.5	9
236	Relationship between the cellular accumulation and the cytotoxicity of S12363, a new vinca alkaloid derivative. Cancer Chemotherapy and Pharmacology, 1992, 29, 367-374.	2.3	7
237	Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity. Biomedical Applications, 1992, 583, 137-143.	1.7	35
238	New .alpha.-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity. Journal of Medicinal Chemistry, 1991, 34, 1998-2003.	6.4	119
239	Approaches to some biochemical mechanisms of action of tuftsin and analogues. Biochemical Pharmacology, 1991, 41, 1411-1418.	4.4	7
240	N-Myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-Myristoyl transferase from L1210 microsomes. FEBS Journal, 1991, 201, 257-263.	0.2	12
241	Assay of tyrosine protein kinase activity from HL-60 by high-performance liquid chromatography for specificity studies. Analytical Biochemistry, 1990, 190, 32-38.	2.4	17
242	Use of the main tyrosine protein kinase activity purified from HL-60 in the search for a new class of anticancer compounds. Anticancer Research, 1990, 10, 197-201.	1.1	8
243	Drug-induced hydrogen peroxide production in isolated rat hepatocytes. Toxicology, 1989, 54, 129-137.	4.2	14
244	Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. European Journal of Cancer & Clinical Oncology, 1989, 25, 1311-1316.	0.7	17
245	Partial purification and characterization of a new p36/40 tyrosine protein kinase from HL-60. Biochemical and Biophysical Research Communications, 1989, 160, 1203-1211.	2.1	10
246	Further validation of the Mulder and van Doorn kinetic procedure for the measurement of microsomal UDP-glucuronosyltransferase activities. Biochemical Journal, 1988, 252, 930-931.	3.7	11
247	Indirect Evidences of Udp-Glucuronosyltransferase Heterogeneity: How Can it Help Purification?. Drug Metabolism Reviews, 1987, 18, 517-551.	3.6	19
248	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mamalian species. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1987, 87, 513-522.	0.2	1
249	In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. European Journal of Medicinal Chemistry, 1987, 22, 393-402.	5.5	6
250	Rat liver microsomal 3Î±-hydroxysteroid dehydrogenase and dihydrodiol dehydrogenase: Solubilization, separation and partial purification. Biochemical and Biophysical Research Communications, 1986, 135, 795-801.	2.1	8
251	Inhibition of microsomal NAD(P)H oxidation by Triton X-100. Journal of Proteomics, 1986, 13, 171-178.	2.4	10
252	Liquid chromatographic assay for the measurement of glucuronidation of arylcarboxylic acids using uridine diphospho-[U-14C]glucuronic acid. Biomedical Applications, 1986, 383, 51-60.	1.7	10

#	Article	IF	Citations
253	Camphoroquinone reduction: another reaction catalyzed by rat liver cytosol 3Î±-hydroxysteroid dehydrogenase. BBA - Proteins and Proteomics, 1986, 870, 463-472.	2.1	18
254	UDP-glucuronosyltransferase(S) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of Triton X-100 activation. Pharmacological Research Communications, 1985, 17, 1005-1015.	0.2	3
255	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Biochemical Pharmacology, 1985, 34, 2235-2249.	4.4	69
256	Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: Comparison between human and mammalian species activities. Chemico-Biological Interactions, 1984, 52, 173-184.	4.0	38
257	Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. Pharmacological Research Communications, 1984, 16, 227-241.	0.2	16
258	Assessment of the Mulder and Van Doorn kinetic procedure and rapid centrifugal analysis of UDP-glucuronosyltransferase activities. Journal of Proteomics, 1984, 9, 69-79.	2.4	40
259	Studies of UDP-glucuronosyltransferase activity toward eugenol, using a gas chromatographic method of measurement. Analytical Biochemistry, 1983, 135, 201-207.	2.4	17
260	Effect of pretreatment with hydroxylated xenobiotics on the activities of rat liver UDP-glucuronosyl-transferases. Xenobiotica, 1983, 13, 755-761.	1.1	11
261	UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. Biochemical Pharmacology, 1981, 30, 2507-2510.	4.4	11
262	How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends. , 0, , .		6